Study examines anticipated ACA reimbursements in ED

This article originally appeared here.
Share this content:
Study Looks at Anticipated ACA Reimbursement Trends in ER
Study Looks at Anticipated ACA Reimbursement Trends in ER

(HealthDay News) -- As a result of implementation of the Affordable Care Act (ACA), outpatient emergency department encounters could reimburse considerably more for both previously uninsured patients who obtain Medicaid coverage and for those who move into private insurance products, according to a study published online Oct. 31 in the Annals of Emergency Medicine.

Jessica E. Galarraga, M.D., M.P.H., and Jesses M. Pines, M.D., M.B.A., from Gorge Washington University in Washington, D.C., conducted a secondary analysis of 2005 to 2010 data from the Medical Expenditure Panel Survey to examine differences in the payments, charges, and reimbursements ratios by insurance category. To reflect likely changes in insurance status after ACA implementation, comparisons were made between two groups: the uninsured who will be Medicaid eligible afterward versus Medicaid insured, and the uninsured who will be Medicaid ineligible afterward versus the privately insured.

The researchers found that, for outpatient emergency department encounters for the previously uninsured who gain Medicaid insurance, reimbursement may increase by 17 percent (40.0 versus 34.0 percent). During the same period, moving Medicaid ineligible patients to private insurance may increase reimbursements by 39 percent (54.0 versus 38.8 percent).

"Although our study does provide insight into the future, multiple factors will ultimately influence reimbursements after implementation of the act," the authors write.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs